Novel Therapeutic Targets for Metastatic Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 16
Special Issue Editor
2. Medical Oncology, IRCCS Azienda Ospedaliero, Universitaria di Bologna, 40138 Bologna, Italy
Interests: thoracic oncology; targeted therapy; immunotherapy; tumor heterogeneity; translational research; drug resistance mechanisms
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Metastatic lung cancer remains a leading cause of cancer-related mortality worldwide, with limited curative options. Recent advances in molecular profiling and immuno-oncology have revealed a variety of novel therapeutic targets beyond classical oncogene drivers, including epigenetic regulators, tumor microenvironment components, and emerging resistance pathways. This Special Issue aims to provide an overview of innovative approaches and recent breakthroughs in identifying and targeting novel vulnerabilities in metastatic lung cancer. We welcome original research articles, reviews, and perspectives exploring new molecular targets, mechanisms of resistance, biomarker development, and strategies to enhance treatment efficacy and overcome immune evasion. Contributions from both preclinical and clinical settings are encouraged.
Dr. Andrea De Giglio
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metastatic lung cancer
- targeted therapy
- immunotherapy
- resistance mechanisms
- tumor microenvironment
- biomarkers
- novel drug targets
- translational oncology
- precision medicine
- epigenetic modulation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
